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What’s new? 
• This appears to be the first time that the representation of people of South Asian 
origin within major clinical trials in diabetes has been systematically and 
quantitatively appraised. 
• The findings not only have implications for necessary caution in the broad application 
of results from major clinical trials, but also point to a need for further improvement 
in the recording and reporting of ethnicity and in ensuring representative ethnic 
balance in trial recruitment. 
 
Abstract 
Aims Our aim was to investigate the proportional representation of people of South Asian 
origin in cardiovascular outcome trials of glucose-lowering drugs or strategies in Type 2 
diabetes, noting that these are among the most significant pieces of evidence used to 
formulate the guidelines on which clinical practice is largely based. 
Methods We searched for cardiovascular outcome trials in Type 2 diabetes published before 
January 2015, and extracted data on the ethnicity of participants. These were compared 
against expected values for proportional representation of South Asian individuals, based on 
population data from the USA, from the UK, and globally. 
Results Twelve studies met our inclusion criteria and, of these, eight presented a sufficiently 
detailed breakdown of participant ethnicity to permit numerical analysis. In general, people 
of South Asian origin were found to be under-represented in trials compared with UK and 
global expectations and over-represented compared with US expectations. Among the eight 
trials for which South Asian representation could be reliably estimated, seven under-
represented this group relative to the 11.2% of the UK diabetes population estimated to be 
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South Asian, with the representation in these trials ranging from 0.0% to 10.0%. 
Conclusions Clinicians should exercise caution when generalizing the results of trials to their 
own practice, with regard to the ethnicity of individuals. Efforts should be made to improve 
reporting of ethnicity and improve diversity in trial recruitment, although we acknowledge 
that there are challenges that must be overcome to make this a reality. 
 
Introduction 
People of South Asian origin are an important target for the prevention and treatment of 
diabetes. In the UK, for instance, Type 2 diabetes is about two times more prevalent in this 
group than in white European people [1]. Furthermore, in the USA, ~ 17.4% of people of 
South Asian origin have diabetes [2]. The risks of diabetic retinopathy and end-stage renal 
disease are known to be higher in South Asian people than in the white European population, 
and individuals of South Asian origin are also known to have a higher mortality rate from 
coronary heart disease and stroke [1]. 
There is also some evidence suggesting that there are ethnic differences in response to 
diabetes therapies. For instance, glucagon-like peptide-1 receptor agonists have been found to 
lower HbA1c levels to a greater extent in Asian-dominant studies than in non-Asian-dominant 
studies, perhaps reflecting a different pathophysiology of Type 2 diabetes in different ethnic 
groups [3]. 
As in other conditions, clinical practice in Type 2 diabetes is influenced heavily by various 
guidelines; these, in turn, are informed by clinical trials, with much weight being placed on 
cardiovascular outcome trials. The applicability of the results from trials to clinical practice is 
dependent on the representativeness of study participants’ demographic characteristics. 
Studies in both acute and chronic conditions, however, have suggested that non-white ethnic 
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groups are often under-represented in clinical trials [4–7]. Here, we report on the proportion 
of participants of South Asian origin recruited to cardiovascular outcome trials of glucose 
lowering in Type 2 diabetes and explore whether proportional ethnic representation was 
achieved in these trials. 
 
Methods 
To identify relevant studies, we took, as a starting point, Holman et al.’s 2014 systematic 
review of cardiovascular outcome trials of glucose lowering in Type 2 diabetes [8]. We 
searched PubMed (MEDLINE) to identify additional relevant studies published after the 
original systematic review, in the period 5 January  2014 to 9 January 2015. In addition to the 
exclusion criteria from the original review, we also excluded studies that involved 
randomization during hospitalization in order to focus on trials exploring glucose lowering in 
the context of general diabetes practice, as opposed to the treatment of acute coronary 
syndromes. 
The abstracts were reviewed by AJ and verified by KK and WH to identify additional 
relevant studies; these were combined with the studies identified in the Holman et al. 
systematic review [8] to provide the full list of studies to be investigated. The additional 
exclusion criterion was also applied to the studies identified by Holman et al. 
The primary publication or baseline data paper for each trial was obtained and the ethnicity 
data were extracted by AJ using a standard form and verified by JG. Following Bhopal [9], 
we used a broad set of terms when extracting ethnicity data, including ‘Asian Indian’, 
‘Indian’, ‘Indian Asian’ and ‘South Asian’. Where relevant, participants were described only 
as ‘Asian’ or the geographic location was stated as ‘Asia’, the number of South Asian 
participants was estimated as 38.9% of the total number from Asia, based on the United 
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Nations world population estimates [10]. 
The calculated percentages for South Asian representation within the trials were compared 
with the proportion of people with diabetes estimated to be of South Asian origin according 
to data from three geographic regions: 11.2% for the UK [1], 2.3% for the USA [2,11,12], 
and 20.6% globally [11]. Comparing the South Asian trial representation with global data 
provides an illustration of the overall applicability of the study data, while the comparisons 
with the UK and US diabetes populations provide country-specific examples for regions that 
have seen different levels of immigration from South Asia. 
For statistical analysis, the binomial exact test with two-tailed P-values was performed, 
comparing South Asian representation within the trials with the expected representation for 
each of the three comparator regions, to explore the likelihood that any differences seen could 
have occurred by chance if there was no differential recruitment. P-values < 0.05 were 
considered to be significant. 
 
Results 
Twenty journal articles were identified by our supplementary literature search, but all were 
excluded after abstract review (Fig. 1). Of the 14 studies identified in the Holman et al. 
systematic review [8], two –Bypass Angioplasty Revascularization Investigation in Type 2 
Diabetes (BARI 2D) and Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial 
Infarction 2 (DIGAMI 2) – were excluded because they involved hospitalized individuals. 
The 12 remaining studies [13–24] are detailed in Table 1 (including expansions of their 
acronyms), along with their estimated breakdown with regard to South Asian participants. 
The nature and reporting of the recruitment of South Asian participants were variable. 
When the representation within trials was compared against the proportion of South Asian 
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people among the diabetes population of the UK, South Asian participants were found to be 
proportionally under-represented in seven of the eight trials (six trials, P < 0.001; UKPDS, 
P = 0.02) and over-represented in ADVANCE (P < 0.001). 
From a US perspective, VADT appears to have proportionally represented South Asian 
individuals (P = 0.368); however, this is based upon the debatable assumption that anyone in 
the trial who was not non-Hispanic white, Hispanic white or black was Asian. By our means 
of analysis, all other studies were deemed to have over-represented people of South Asian 
origin when considering the US population with diabetes, except Look AHEAD and 
ACCORD, which under-represented people of South Asian origin (all P < 0.001). 
From a global perspective, all eight trials that were numerically analysed were found to have 
proportionally under-represented South Asian participants compared with the expected 
proportion estimate (all P < 0.001). 
Finally, none of the identified trials reported outcomes separately according to ethnicity; 
however, one UKPDS publication investigated the characteristics of people of different 
ethnic origins at diagnosis of diabetes in the study population [25]. 
 
Discussion 
A lack of proportional representation in trials is of particular significance in conditions for 
which ethnicity may have an impact on outcomes, as is thought to be the case for Type 2 
diabetes. In general, our analysis of cardiovascular outcome trials of glucose-lowering 
therapies shows under-representation of South Asian participants in trials when compared 
against the UK and global diabetes populations, and over-representation when compared 
with the US population. 
Another finding, and one that represents a limitation of our analysis, is that the reporting of 
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ethnicity within published trial reports was not optimal, with several papers failing to 
provide a breakdown that included Asian or South Asian categories. (In our analysis, 
several of the key values in Table 1 had to be derived by estimation.) Reporting standards 
in the area of ethnic breakdowns could be improved significantly. 
A further consideration is that, even where the values are accurate, the trial populations 
may not truly represent the global, UK or US populations of South Asian origin, as this 
group is in turn made up of a number of subpopulations, and the ratios in the trials may be 
different from those in clinical practice. 
We acknowledge that no clinical trial is likely to be truly ‘global’ in scope with study sites in 
all countries of the world. Nevertheless, there is a growing desire for inclusion of a more 
diverse population in clinical trials [5,26]. In the USA, for instance, the lack of proportional 
representation in studies funded by the National Institutes of Health (NIH) was highlighted 
by the NIH Revitalization Act of 1993, which mandated the appropriate inclusion of minority 
ethnic groups in research projects supported by the body [27]. A federal Executive Order in 
2009 [28] has further contributed to an increased research focus on Asian Americans. 
However, there remains a lack of global guidance relating to the issue of proportional 
representation. 
For greater diversity in the populations recruited for trials to become a reality, a number of 
barriers needs to be overcome (with a potential role existing for researchers in the UK, for 
instance, supporting researchers in South Asia) [5]. As an example, new recruitment 
strategies and enhanced logistical support will be required to provide researchers with 
information about different ethnic groups and to ensure that engagement is both culturally 
appropriate and sustainable [5]. This might include developing translated materials related 
to the trial and the use of interpreters to ensure that participants fully understand what 
participation entails. The Prevention of Diabetes and Obesity in South Asians (PODOSA) 
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trial investigators reported on their experiences of recruiting South Asian people to 
participate in their trial and suggested that a community-orientated, personal approach was 
most successful [29]. The importance of health literacy, general literacy and numeracy in 
this process should not be underestimated. 
We propose that clinicians across the world exercise caution in generalizing the results of 
trials to their own practice, with regard to individuals’ ethnicity. We also call for improved 
diversity in trial recruitment, while acknowledging that there are challenges that must be 
overcome in order to make this a reality. Finally, we recommend developing an evidence 
base that highlights where there is a clinical imperative for tailored strategies for different 
ethnic groups, with potentially significant benefits for the populations concerned and also 
for healthcare economies. 
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FIGURE 1 Flow chart illustrating the process used to identify studies included in the analysis. 
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Table 1 Representation of South Asian participants included in cardiovascular outcome trials of glucose 
lowering in Type 2 diabetes 
Study Year of 
primary 
publicati
on 
N Ethnicity 
demographics 
relating to South 
Asian participants 
Proportion of participants estimated to be of South 
Asian origin, and comparison with proportion of South 
Asian individuals in global, US and UK diabetes 
populations 
Descript
or 
Proporti
on of 
trial 
populati
on (%, 
n) 
Estimated 
representati
on of South 
Asian trial 
participants
†
 (%, n) 
Difference 
from 
expected 
global 
representati
on (%) 
Difference 
from 
expected 
US 
representati
on (%) 
Difference 
from 
expected 
UK 
representati
on 
UKPDS 
[13] 
1998 3 867 Indian 
Asian 
10 (387) 10.0 (387) –10.6* +7.7* –1.2** 
ProACTI
VE [14] 
2005 5 238 Non-
white 
1.4 (74) Could not 
be reliably 
estimated 
– – – 
ACCORD 
[15] 
2008 10 25
1 
Non-
white 
0 (0) 0 (0) –20.6* –2.3* –11.2* 
ADVANC
E [16] 
2008 11 14
0 
Asia 37.1 
(4136) 
14.4 (1608) –6.2* +12.1* +3.2* 
HEART2
D [17] 
2009 1 115 India 6.3 (70) 6.3 (70) –14.3* +4.0* –4.9* 
VADT 
[18] 
2009 1 791 Not 
white 
(Hispani
c or 
non-
5.0 (90) 2.0 (35) –18.6* –0.3*** –9.2* 
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Hispani
c) or 
black 
RECORD 
[19] 
2009 4 447 Not 
white 
1.1 (48) Could not 
be reliably 
estimated 
– – – 
ADDITIO
N-Europe 
[20] 
2011 2 941 Not 
white 
5.3 
(156) 
Could not 
be reliably 
estimated 
– – – 
ORIGIN 
[21] 
2012 12 61
2 
India 3.1 
(390) 
3.1 (390) –17.5* +0.8* –8.1* 
SAVOR-
TIMI 53 
[22] 
2013 16 49
2 
Other 
(not 
white or 
Hispani
c) 
3.3 
(544) 
Could not 
be reliably 
estimated 
– – – 
EXAMIN
E [23] 
2013 5 380 Asian 20.2 
(1089) 
7.9 (423) –12.7* +5.6* –3.3* 
Look 
AHEAD 
[24] 
2013 5 145 Asian or 
Pacific 
Islander 
1.0 (50) 0.4 (19) –20.2* –1.9* –10.8* 
*P < 0.001; **P = 0.02; ***P = 0.368. 
†If a broad Asian category was presented, the proportion of South Asians was determined as 0.389 × actual 
Asia/Asian population (this was a conservative estimate – with regard to testing for under-representation of 
South Asian participants – in the case of Look AHEAD, for which the ethnic descriptor included Pacific 
Islanders). 
ACCORD, Action to Control Cardiovascular Risk Diabetes trial; ADDITION, Anglo-Danish-Dutch Study of 
Intensive Treatment in People with Screen Detected Diabetes in Primary Care; ADVANCE, Action in Diabetes 
and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; EXAMINE, Examination of 
Cardiovascular Outcomes with Alogliptin versus Standard of Care; HEART2D, Hyperglycemia and Its Effect 
After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus; 
Look AHEAD, Look Action for Health in Diabetes; ORIGIN, Outcome Reduction with an Initial Glargine 
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Intervention; ProACTIVE, Prospective Pioglitazone Clinical Trial in Macrovascular Events; RECORD, 
Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes; 
SAVOR-TIMI, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–
Thrombolysis in Myocardial Infarction; UKPDS, UK Prospective Diabetes Study; VADT, Veterans Affairs 
Diabetes Trial. 
 
 
 
 
 
